The Gilead UK & Ireland Fellowship and Medical Grant Programme (GFP), invites applications from healthcare and third sector organisations across the UK and Ireland that are working to improve care and quality of life for people living with HIV, cancer and liver disease.
Gilead Sciences is an American biopharmaceutical company headquartered in Foster City, California. It specializes in researching, developing, and commercializing innovative medicines for life-threatening diseases, with a primary focus on three core areas: virology, oncology, and inflammation.
Applications are invited from not-for-profit healthcare-focused organisations across the United Kingdom and Ireland. Supported projects are expected to provide measurable outcomes and positive impacts for patients, healthcare systems, and affected communities.
The deadline for applications is Friday 31 July 2026.
The programme focuses on improving care and quality of life for people affected by HIV, cancer, and liver disease, supporting innovative and high-impact projects, delivering measurable benefits to patients and healthcare providers, strengthening community support, healthcare-focused initiatives, sustainability planning, programme development, educational activities, and healthcare improvement within Gilead’s therapeutic areas of expertise.
Applicants are required to submit detailed project information as part of the application process. This includes organisation contact information, therapeutic area of focus, total project budget, funding amount requested, project timelines, anticipated reach, countries of implementation, organisation overview, programme description, objectives, planned activities, expected outcomes, sustainability plans, and a detailed budget breakdown.
Applications must also include supporting documentation such as an annual report or tax document, a letter of support, a new supplier form, and a signed finance department letter confirming bank details.
The programme supports projects implemented within the United Kingdom and Ireland only and is intended to help organisations develop and deliver impactful healthcare initiatives aligned with the programme’s therapeutic priorities.
The programme has multiple funding application windows scheduled across 2026, covering different therapeutic areas, for example:
- HIV: 9 March – 12 June 2026
- Viral Hepatitis & BBV Testing: 1 April – 22 May 2026
- CAR T: 6 April – 6 July 2026, and
- Oncology: 5 May – 31 July 2026
Gilead also has a Community Grants scheme, for which registration is required. The scheme is designed to enable Gilead to work with patient advocates, non-profits and healthcare professionals across all its therapeutic areas of focus to improve care through partnerships and community engagement.
For further information about the Gilead Fellowship Medical Grant Programme and the Community Grants scheme, please visit the Gilead website.